IRIDEX

IRIDEX Corp. engages in developing, manufacturing, and marketing medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. Its products include lasers, laser delivery and glaucoma devices, retinal surgical instruments, veterinary, and ENT. The company was founded by Eduardo Arias, Theodore A. Boutacoff, David M. Buzawa and James L. Donovan in February 1989 and is headquartered in Mountain View, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IRIDEX reports Q1 revenue decline, explores strategic growth opportunities

IRIDEX faces challenges with longer sales cycles and margin pressure but maintains leadership in its core business areas.
Strategic discussions for potential transactions offer growth opportunities for the company and its stockholders.
Addressing revenue decline in retina products and improving cash position are key focus areas for future performance.

IRIDEX reports Q3 mixed results, focuses on cost-cutting and growth

IRIDEX reported mixed financial performance in Q3 2024 with a decline in total revenue but growth in Cyclo G6 product sales.
Efforts to address cash burn through cost-cutting measures and strategic review progress were highlighted.
Challenges in the retina business were noted, but opportunities for improvement in glaucoma products and cost efficiencies were emphasized.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter 2024 and provide a business update after the close of trading on Tuesday, November 12, 2024.

Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024

MOUNTAIN VIEW, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the appointment of Patrick Mercer as the Company's Chief Executive Officer and President effective October 1, 2024. Previously Mr. Mercer served as the Company's Chief Operating Officer and President. David Bruce, the Company's prior Chief Executive Officer, is transitioning from the Company. Coincident to Mr. Mercer's appointment, Scott Shuda was appointed Executive Chairman of the Company's board of directors. Mr. Shuda had previously served as Chairman.

Iridex Appoints Patrick Mercer as Chief Executive Officer

IRIDEX has faced delays in selling its assets as part of a strategic review initiated a year ago, causing frustration among shareholders. Despite setbacks, the company remains committed to selling all assets and has taken steps to ensure financial sustainability during the process. The CEO expects agreements for the sale of assets by the end of 2024, potentially doubling the current share price within the next 3-6 months.

Iridex Frustrates, But Expect A Transaction By Year-End

IRIDEX Corporation (NASDAQ:IRIX ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Philip Taylor – Investor Relations David Bruce – Chief Executive Officer Fuad Ahmad – Interim Chief Financial Officer Conference Call Participants Tom Stephan – Stifel Operator Good day, and thank you for standing by. At this time I would like to welcome everyone to IRIDEX Second Quarter 2024 Earnings Conference Call.

IRIDEX Corporation (IRIX) Q2 2024 Earnings Call Transcript

Iridex (IRIX) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.17 per share a year ago.

Iridex (IRIX) Reports Q2 Loss, Misses Revenue Estimates

IRIDEX Corporation (NASDAQ:IRIX ) Q1 2024 Earnings Conference Call May 14, 2024 5:00 PM ET Company Participants Trip Taylor - Investor Relations David Bruce - Chief Executive Officer Fuad Ahmad - Interim Chief Financial Officer Conference Call Participants Tom Stephan - Stifel Operator Good day, and thank you for standing by. Welcome to Q1 2024 IRIDEX Earnings Conference Call.

IRIDEX Corporation (IRIX) Q1 2024 Earnings Call Transcript

Iridex (IRIX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.13 per share a year ago.

Iridex (IRIX) Reports Q1 Loss, Misses Revenue Estimates

MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 30, 2024, and provided a business update.

Iridex Reports First Quarter 2024 Financial Results

Iridex Corporation is undergoing a strategic review process to unlock shareholder value. The company is likely to sell its retina business line and potentially parse it out in more than one transaction "soon." The glaucoma business line is highly promising but likely needs to be in the hands of a bigger company to reach its full potential.

Iridex's Strategic Review Process Should Bear Fruit 'Soon'

IRIDEX Corporation (IRIX) Q4 2023 Earnings Call Transcript

Iridex (IRIX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.07 per share a year ago.

Iridex (IRIX) Reports Q4 Loss, Lags Revenue Estimates

MOUNTAIN VIEW, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended December 30, 2023, and provided a business update.

Iridex Reports Fourth Quarter and Full Year 2023 Financial Results

MOUNTAIN VIEW, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced it will release financial results for the fourth quarter and full year 2023 and provide an update on its strategic review process after the close of trading on Tuesday, March 26, 2024.

Iridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024

Cutera

MicroVision

The Zacks Laser Systems and Components industry participants like MicroVision (MVIS), Cutera (CUTR) and IRIDEX Corporation (IRIX) gain from solid demand for emerging applications like autonomous driving, IoT, 5G and healthcare amid challenging macroeconomic conditions.

3 Laser Systems Stocks to Watch in a Challenging Industry

MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, headquartered in Mountain View, California, and Imperial College Healthcare NHS Trust in London, today announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse® Transscleral Laser Therapy (TLT) using Iridex' Cyclo G6® Laser and the MicroPulse P3® Delivery Device. This partnership establishes a large-scale enrollment platform to advance clinical research.

Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust

MOUNTAIN VIEW, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, a global leader in innovative laser-based medical systems for the treatment of eye diseases, proudly announces the US launch of its next-generation platform Iridex 532® and Iridex 577® Lasers alongside its 35th anniversary celebration. The announcement was made ahead of their official showcase at the Hawaiian Eye and Retina 2024 Meeting from January 13-19, 2024.

Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma

Action Retains Full Patient Access to MicroPulse® Transscleral Laser Treatment Action Retains Full Patient Access to MicroPulse® Transscleral Laser Treatment

Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation

MOUNTAIN VIEW, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its successful advocacy for revision of the recently issued Medicare Local Coverage Determinations (LCDs) for Cyclophotocoagulation (CPC).

Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation

MOUNTAIN VIEW, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.

Iridex Reports Third Quarter 2023 Financial Results and Business Update

The Company also announced plans to present at Stifel Healthcare Conference The Company also announced plans to present at Stifel Healthcare Conference

Iridex to Host Third Quarter Financial Results Conference Call on November 14, 2023

IRIDEX Corporation's shares rallied over the past several weeks on news it was conducting a strategic review. On November 1, the stock cratered as the company disclosed possible concerns with Medicare reimbursement for certain glaucoma procedures. The impact of this new ruling related to IRIX's business is limited, with only about 10% of revenue affected.

Iridex Reimbursement Chaos Presents Buying Opportunity

MOUNTAIN VIEW, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2023 after the close of trading on Tuesday, November 14, 2023.

Iridex to Report Third Quarter Financial Results on November 14, 2023

IRIDEX Corporation is a leading provider of laser-based retinal treatments and is respected in the ophthalmic industry. IRIX stock has experienced a significant decline in value, but the primary reason for this (dilution concerns) is misguided. The company is undergoing a strategic review and may separate its two divisions, which could significantly benefit shareholders.

Iridex: The Whole Is Less Than The Sum Of The Parts

MOUNTAIN VIEW, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) announced today that its Board of Directors is undertaking, in consultation with its financial and legal advisors, a review and evaluation of strategic alternatives that may be available to the Company to unlock shareholder value. Iridex has engaged Piper Sandler to act as financial advisor in connection with the strategic review process.

Iridex Announces Strategic Review to Unlock Shareholder Value

IRIDEX Corporation (NASDAQ:IRIX ) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Philip Taylor - Gilmartin Group David Bruce - President, CEO & Director Fuad Ahmad - Interim Chief Financial Officer Conference Call Participants Scott Henry - ROTH Capital Partners Thomas Stephan - Stifel, Nicolaus & Company Operator Good day, and thank you for standing by. Welcome to the Second Quarter 2023 IRIDEX Earnings Conference Call.

News for IRIDEX Stock (IRIX)